The University of Florida, a founding member of the DPT-1 and the internationally constituted diabetes trial network (Type 1 Diabetes TrialNet), has made significant and important contributions to TrialNet and type 1 diabetes (T1D), where it participates as one of the top performing Clinical Centers. The primary goal of TrialNet is to prevent and/or delay the development of T1D in persons at risk for the disease by testing interventions targeted at decreasing ?-cell destruction and/or enhancing ?-cell survival. The University of Florida seeks to continue serving as a Clinical Center as part of the TrialNet network. The NIH TrialNet RFA intends to continue providing support for highly productive centers by funding the necessary infrastructure that would enable screening large numbers of T1D relatives so as to identify those at risk of clinical disease. Continuing TrialNet membership would enable our established and highly successful University of Florida Clinical Center and its strong Affiliate network to continue supporting subject recruitment into studies, enhancing trial performance, subject retention, and follow-up. Indeed, our Center is poised to continue the quest for the future prevention and reversal of T1D through its outstanding environment and innovative investigators with proven approaches, each dedicated to identifying a means to prevent/cure the disease as well as to enhance recruitment and retention for T1D clinical trials. In responding to this RFA, this application describes: 1) Unique strengths and contributions of the institution to TrialNet and the T1D field;2) Ongoing and novel strategies to identify and maintain an active Affiliate network;3) Recruitment, outreach, and collaboration plans;4) Strategies to enhancing cost efficiency;5) Performance monitoring;6) Consideration of federated IRB;7) Development of future T1D clinical researchers;and 8) Potential opportunities and challenges for the prevention of T1D currently and over the next 5 years.

Public Health Relevance

Each year, over 20,000 children and adolescents, as well as a similar number of adults, are diagnosed in the U.S. with type 1 diabetes (T1D). The disease represents a tremendous burden for the both two million Americans having the disorder and society as well, given significant short- and long term complications notwithstanding the tremendous financial costs. The NIH-supported T1D TrialNet Clinical Network is designed to disrupt this cycle through recruitment of non-diabetic, but at-risk individuals. This, for the purpose of undertaking therapies aimed at preventing or delaying the development this disease.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-J (M2))
Program Officer
Leschek, Ellen W
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Florida
Schools of Medicine
United States
Zip Code
Ismail, Heba M; Xu, Ping; Libman, Ingrid M et al. (2018) The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes. Diabetologia 61:84-92
Culina, Slobodan; Lalanne, Ana Ines; Afonso, Georgia et al. (2018) Islet-reactive CD8+ T cell frequencies in the pancreas, but not in blood, distinguish type 1 diabetic patients from healthy donors. Sci Immunol 3:
Vecchio, Federica; Lo Buono, Nicola; Stabilini, Angela et al. (2018) Abnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes. JCI Insight 3:
Redondo, Maria J; Steck, Andrea K; Sosenko, Jay et al. (2018) Transcription Factor 7-Like 2 (TCF7L2) Gene Polymorphism and Progression From Single to Multiple Autoantibody Positivity in Individuals at Risk for Type 1 Diabetes. Diabetes Care 41:2480-2486
Sanda, Srinath; Type 1 Diabetes TrialNet Study Group (2018) Increasing ICA512 autoantibody titers predict development of abnormal oral glucose tolerance tests. Pediatr Diabetes 19:271-276
Yeo, Lorraine; Woodwyk, Alyssa; Sood, Sanjana et al. (2018) Autoreactive T effector memory differentiation mirrors ? cell function in type 1 diabetes. J Clin Invest 128:3460-3474
Redondo, Maria J; Geyer, Susan; Steck, Andrea K et al. (2018) A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. Diabetes Care 41:1887-1894
Greenbaum, Carla J; Speake, Cate; Krischer, Jeffrey et al. (2018) Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience. Diabetes 67:1216-1225
Haller, Michael J; Schatz, Desmond A; Skyler, Jay S et al. (2018) Low-Dose Anti-Thymocyte Globulin (ATG) Preserves ?-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes. Diabetes Care 41:1917-1925
Redondo, Maria J; Geyer, Susan; Steck, Andrea K et al. (2018) TCF7L2 Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes. Diabetes Care 41:311-317

Showing the most recent 10 out of 68 publications